Skip to main content

Shanmugam Muthusamy's Form 4 filing

Ani Pharmaceuticals Inc (ANIP) · filed Mar 7, 2024

Accession no.
0001870913-24-000010
Filed
Mar 7, 2024
Trade date
Mar 5-7, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $2.63M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shanmugam MuthusamyCIK 0001870913Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 5, 2024Common StockSSaleDisposed−10,093$65.35F2−$659,577.55872,527Indirect
Mar 6, 2024Common StockSSaleDisposed−14,822$65.47F4−$970,396.34857,705Indirect
Mar 7, 2024Common StockSSaleDisposed−15,085$66.35F5−$1,000,889.75842,620Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $64.45 to $66.58, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $64.84 to $66.04, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $65.53 to $67.00, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)